SCHEMBL20915137

SCHEMBL20915137

C#C[C]1CCC2C3CCC4=CC(=O)CCC4C3CC[C@@]12CC

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 6/20 0.59
▸ LMNA P02545 5/20 0.59
▸ CYP3A4 P08684 5/20 0.59
▸ AR P10275 5/20 0.59
▸ SLC6A4 P31645 4/20 0.59
▸ ABCB11 O95342 4/20 0.59
▸ MEN1 O00255 3/20 0.59
▸ KMT2A Q03164 3/20 0.59
▸ ESR1 P03372 3/20 0.59
▸ SHBG P04278 3/20 0.59
▸ NR3C1 P04150 3/20 0.59
▸ CYP2C19 P33261 3/20 0.59
▸ POLB P06746 1/20 0.59
▸ CYP19A1 P11511 2/20 0.56
▸ ALDH1A1 P00352 2/20 0.53
▸ TSHR P16473 1/20 0.53
▸ HIF1A Q16665 1/20 0.53
▸ ADRA2A P08913 1/20 0.53
▸ OPRM1 P35372 1/20 0.52
▸ SLC22A1 O15245 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20851687 0.85 CYP19A1 (0.69) PGRLMNACYP3A4ARSLC6A4
SCHEMBL3182567 0.85 CYP19A1 (0.69) PGRLMNACYP3A4ARSLC6A4
SCHEMBL1422567 0.85 CYP19A1 (0.69) PGRLMNACYP3A4ARSLC6A4
SCHEMBL11629999 0.85 CYP19A1 (0.69) PGRLMNACYP3A4ARSLC6A4
SCHEMBL16661457 0.85 CYP19A1 (0.69) PGRLMNACYP3A4ARSLC6A4
SCHEMBL11629995 0.85 CYP19A1 (0.69) PGRLMNACYP3A4ARSLC6A4
SCHEMBL22845080 0.85 CYP19A1 (0.69) PGRLMNACYP3A4ARSLC6A4
SCHEMBL22364339 0.84 NR1I2 (0.62) PGRLMNACYP3A4ARSLC6A4
SCHEMBL4107677 0.81 CYP19A1 (0.57) PGRLMNACYP3A4ARSLC6A4
SCHEMBL13372857 0.80 CYP19A1 (0.56) PGRLMNACYP3A4ARSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3697421-B1 LONGER-ACTING PROGESTIN PRODRUG CONTRACEPTIVES EVESTRA INC (US) 2024-04-17 — — EP disclosed
US-10624903-B2 Longer-acting progestin prodrug contraceptives EVESTRA, INC. (US) 2020-04-21 — — US disclosed
US-20190117670-A1 LONGER-ACTING PROGESTIN PRODRUG CONTRACEPTIVES EVESTRA, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190117670-A1 LONGER-ACTING PROGESTIN PRODRUG CONTRACEPTIVES CYP19A1, PGR, GNRHR PGR 2/4885LMNA 2263/4885CYP3A4 35/4885
US-10624903-B2 Longer-acting progestin prodrug contraceptives CYP19A1, PGR, GNRHR PGR 2/4885LMNA 2263/4885CYP3A4 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback